Condition

Immune Checkpoint Inhibitors clinical trials and research

• 11Clinical trials
• 45NIH research projects
• 9Countries

Newest Immune Checkpoint Inhibitors clinical trials

All recruiting trials (11)

• Adjuvant sintilimab after neoadjuvant therapy and surgery for high-risk NSCLC

  This trial tests whether giving sintilimab after surgery helps prevent cancer from returning in people with high-risk non-small cell lung cancer who already had neoadjuvant immunochemotherapy and surgery.

  Recruiting at 2 sites Phase 2 Sichuan University · Chengdu, Sichuan and 1 other locations · NCT07748325

• Predictive biomarkers for immunotherapy in endometrial cancer

  This study tests molecular and epigenetic features to see if they can predict which endometrial cancer patients will respond to immune checkpoint inhibitors.

  Recruiting European Institute of Oncology · Milan, Italy · NCT07690540

• Observational cohort of chronic brain viral infections (including PML)

  This project will try immune checkpoint inhibitors in people with chronic central nervous system viral infections like PML to see if they lead to better long-term outcomes.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07512518

• Neoadjuvant therapy for early triple-negative breast cancer using QL1706 plus chemotherapy guided by response

  This study tests if adding QL1706 (a PD-1/CTLA-4 blocker) to chemotherapy before surgery can shrink early triple-negative breast tumors and spare some patients from anthracyclines.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07372079

• Electroacupuncture plus immunotherapy after surgery for early non-small cell lung cancer

  This trial tests whether adding electroacupuncture (and in some groups a Zilongjin herbal tablet) to immune checkpoint inhibitor treatment after surgery helps people with stage II–III non‑small cell lung cancer reduce recurrence and live longer.

  Recruiting Phase 2/3 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin · NCT07034326

• Exploring how sleep disturbances affect lung cancer treatment outcomes

  This study is trying to see how sleep problems affect the success of immune treatments in people with lung cancer.

  Recruiting Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT06975384

• Using durvalumab with chemotherapy for muscle-invasive bladder cancer

  This study is testing if adding a new immune therapy called durvalumab to standard chemotherapy can help people with muscle-invasive bladder cancer before they have surgery.

  Recruiting at 48 sites Phase 2 AstraZeneca · Chermside and 58 other locations · NCT06960577

• Understanding the impact of immune-related side effects in arthritis patients after immunotherapy

  This study looks at how immune-related side effects from immunotherapy affect the daily lives of arthritis patients and what they think about these experiences.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT06647134

• Fruquintinib treatment for advanced liver cancer after immunotherapy

  This study is testing if a new drug called fruquintinib can help people with advanced liver cancer who haven't responded well to previous immunotherapy treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06446154

• Identifying biomarkers for immune-related side effects in cancer patients receiving immunotherapy

  This study is trying to find out if certain blood markers can help predict which cancer patients receiving immunotherapy are more likely to experience serious side effects.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT05813418

• Exploring how psychological stress affects lung cancer treatment outcomes

  This study is trying to see how psychological stress affects the success of immune treatments for different types of lung cancer patients.

  Recruiting Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT05477979

NIH-funded research (newest 40 of 45)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients

  This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.

  NIH research Yale University · New Haven, United States · NIH-11603643

• Gut bacteria that can make cancer immunotherapy less effective

  This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11478145

• Decoding how NSCLC patients respond and react to immunotherapy through noninvasive blood tests and tumor samples

  A study in people with non-small cell lung cancer will look at blood and tumor samples to understand why some patients benefit from immunotherapy and who might have serious side effects.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11443925

• Understanding skin reactions from immune cancer drugs and how our body’s immune system reacts to them

  This grant explores why some people develop severe skin reactions when treated with immune checkpoint inhibitors and aims to use patient data and tissue studies to improve care.

  NIH research Vanderbilt University Medical Center · Nashville, United States · NIH-11437973

• Targeting NNMT in the tumor environment to make immunotherapy work better

  Aiming to boost cancer treatment by blocking NNMT in the tumor’s supportive tissue so immune therapies work more effectively.

  NIH research University of Chicago · Chicago, United States · NIH-11434745

• Using JAK inhibitors to calm autoimmune damage from cancer immunotherapy

  A multi-center, early-phase trial will test whether a JAK inhibitor can help people who develop diabetes caused by cancer immunotherapy.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11426254

• Germline genetic clues for immune-related side effects from cancer immunotherapy

  A large study will look at inherited genetic differences to understand why some cancer patients develop immune-related side effects from checkpoint inhibitors.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11415733

• Novel combo therapy using oncolytic adenovirus and immune drugs for pancreatic cancer

  Aims to combine an oncolytic virus with immune therapies to help shrink pancreatic tumors before surgery and keep them from coming back.

  NIH research Uinta Bio, INC. · Park City, UNITED STATES · NIH-11407396

• Survivors living with advanced cancer after durable response to immune therapy

  This grant follows people who had advanced cancer and responded well to immune checkpoint inhibitors to understand what helps them stay well and how their symptoms change over time.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11401364

• Harnessing neutrophils to boost immune therapy for breast cancer

  Aims to find neutrophil signals that predict and improve how well immune checkpoint therapies work for breast cancer patients.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11397566

• Targeting NRF2 to help head and neck cancer respond better to immunotherapy

  Aims to boost immune therapy effectiveness for head and neck cancer by blocking NRF2, a cancer support pathway, in patients whose tumors have NRF2 activation.

  NIH research Washington University · Saint Louis, United States · NIH-11389337

• Immune checkpoint drugs and faster buildup of heart artery plaques in cancer patients

  This study will follow melanoma patients treated with immune checkpoint inhibitors to see if these cancer drugs speed up coronary artery plaque buildup.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11389288

• Targeted alpha-particle therapy combined with immune checkpoint drugs for melanoma

  A new targeted alpha-particle treatment paired with immune checkpoint drugs for people with advanced melanoma.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11336464

• Adaptive symptom self-management to ease distress for cancer survivors on immune checkpoint inhibitors

  A study tests a phone-based symptom-monitoring program, with tailored support, to help cancer survivors on immune checkpoint inhibitors feel less distressed and manage side effects.

  NIH research University of Arizona · Tucson, United States · NIH-11326259

• Blocking Pyk2 to help immune therapy work better for glioblastoma

  Seeing if stopping a protein called Pyk2 can make immune checkpoint drugs (like PD-L1 blockers) work better for people with glioblastoma.

  NIH research Universidad Central Del Caribe · Bayamon, United States · NIH-11325413

• Catheter-guided nanoparticle delivery of anti–PD-L1 immunotherapy to liver tumors

  It delivers PD-L1 blocking immunotherapy directly into liver tumors through a catheter using nanoparticle carriers for people with hepatocellular carcinoma.

  NIH research Northwestern University · Chicago, United States · NIH-11294290

• Symptoms and quality of life during immunotherapy for metastatic cancer

  The team will track symptoms and day-to-day quality of life in people with metastatic cancer who are receiving immune checkpoint inhibitor treatments.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11267220

• Heart inflammation caused by cancer immunotherapy

  Researchers are learning how immune-checkpoint cancer drugs can trigger dangerous heart inflammation so future patients can be protected.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11248804

• How inherited immune genes affect response to cancer immunotherapy

  This project looks at whether people's inherited immune genes change how well immunotherapy works for breast cancer.

  NIH research Jackson Laboratory · Bar Harbor, United States · NIH-11247469

• Using enhanced natural killer cells to treat lung cancer patients who don't respond to standard therapies

  This study is looking at a new way to help people with non-small cell lung cancer who haven't had success with current immune treatments by boosting special immune cells called NK cells to better fight the cancer.

  NIH research University of California-Irvine · Irvine, United States · NIH-11194340

• Inherited genes that affect immune side effects from cancer immunotherapy

  This project looks for inherited genetic differences that help explain why some people get serious immune side effects from checkpoint inhibitor cancer treatments.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11193785

• Boosting immune therapy in PTEN‑deficient prostate cancer by targeting the cGAS/STING pathway

  This project tests drugs that turn on the cGAS/STING immune switch to help immune checkpoint medicines work better for men with PTEN‑deficient metastatic prostate cancer.

  NIH research University of Chicago · Chicago, United States · NIH-11169704

• Survivorship after lasting benefit from immunotherapy for advanced cancer

  This project follows people with advanced cancers who have had long-lasting benefit from immunotherapy to track their health, symptoms, and care needs over time.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11168670

• Vaccines Targeting Cancer Markers with Immunotherapy for Pancreatic Cancer

  This project explores combining special vaccines with existing immunotherapies to help the body's immune system fight pancreatic cancer.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11115878

• Helping cancer survivors manage symptoms and reduce distress during treatment

  This study is testing a helpful phone system that lets cancer survivors share their symptoms each week, so their healthcare team can quickly support them, especially if they're feeling really stressed, making it easier for them to manage their health during treatment.

  NIH research University of Arizona · Tucson, United States · NIH-11078665

• Targeted delivery of immune therapy for liver cancer treatment

  This study is looking at a new way to treat liver cancer by using tiny carriers to deliver immune therapy right to the tumor, which could make the treatment work better and cause fewer side effects, and patients may have a chance to try this promising approach for better results.

  NIH research Northwestern University at Chicago · Chicago, United States · NIH-11062425

• Blocking Pyk2 to improve immune therapy for aggressive brain cancer

  This study is looking at how blocking a protein called Pyk2 might help make glioblastoma, a tough brain cancer, more sensitive to treatments that use the immune system, so that patients can have better responses to their therapies.

  NIH research Universidad Central Del Caribe · Bayamon, United States · NIH-11059876

• Understanding heart inflammation caused by cancer immunotherapy

  This study is looking at how certain cancer treatments can sometimes cause heart inflammation, and it's using mice to help understand why this happens so that doctors can find better ways to protect patients' hearts while they receive these therapies.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11050243

• Understanding how genetics influence responses to cancer immunotherapy

  This study is looking at how different genes in a person's body can affect how well cancer treatments called immune checkpoint inhibitors work, with the goal of finding out which patients might benefit the most from these therapies.

  NIH research Jackson Laboratory · Bar Harbor, United States · NIH-11048708

• Understanding side effects and quality of life for diverse patients using immune therapies for cancer.

  This study is looking at how different people with advanced cancer feel while getting immune checkpoint inhibitors, focusing on their side effects and quality of life, to help improve support and care for patients like you.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11040016

• How gut bacteria affect cancer treatment effectiveness

  This study is looking at how the bacteria in your gut might affect how well cancer treatments called immune checkpoint inhibitors work, and it hopes to find new ways to improve these treatments by using ideas from fecal transplants without the hassle.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11032419

• Combining targeted radiation therapy with immune treatments for melanoma

  This study is exploring a new way to treat advanced melanoma, a serious skin cancer, by using a special therapy that targets a specific receptor in melanoma cells, hoping to make current treatments work better for patients like you.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11025900

• Investigating kidney injury in cancer patients using immune checkpoint inhibitors and antibiotics

  This study is looking at how certain cancer treatments can sometimes harm the kidneys, especially when used with common antibiotics, to help doctors find ways to spot and prevent kidney problems early, making treatment safer for patients.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-10998392

• Understanding heart risks from cancer immunotherapy

  This study is looking at how cancer treatments called immune checkpoint inhibitors might affect the heart, especially in patients with certain heart markers, to help figure out who can safely keep using these treatments even if they have heart symptoms.

  NIH research Stanford University · Stanford, United States · NIH-10996621

• Understanding side effects of new cancer treatments using patient feedback

  This study is looking to hear from cancer patients about the side effects they experience while receiving combination treatments that include immune checkpoint inhibitors, so we can better understand and manage any unique challenges that come with these therapies.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10989909

• Understanding genetic factors behind immune-related side effects of cancer treatments

  This study is looking at how certain genes might affect the side effects that cancer patients experience when they receive immune therapy, with the hope of making these treatments safer and more effective for everyone.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-10942344

• Understanding how some advanced cancer patients benefit long-term from immune therapies

  This study is looking at patients with advanced cancer who have had lasting positive results from certain immune treatments, to learn more about what helps them live longer and how to support their needs better.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-10929397

• Investigating a pathway to improve immune responses in prostate cancer patients

  This study is looking at how to make cancer treatments work better for men with advanced prostate cancer that has stopped responding to hormone therapy, especially those whose tumors have lost a specific gene, by exploring ways to boost the immune system's ability to fight the cancer.

  NIH research University of Chicago · Chicago, United States · NIH-10911174

• Understanding how immune checkpoint inhibitors interact with other medications

  This study is looking at how cancer treatments called immune checkpoint inhibitors might interact with other medications you’re taking, to help make sure they work safely and effectively together.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-10896252

• Monitoring cancer treatment response using exosomes in lung cancer patients

  This study is looking at how tiny particles in your blood, called exosomes, can help doctors see how well certain cancer treatments are working for people with non-small cell lung cancer, so they can better tailor the treatment to each patient without needing to do any painful procedures.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-10890842

Related topics

Quick answers

How many Immune Checkpoint Inhibitors clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 9 countries. The most sites are in China (7 trials), France (2 trials), Italy (2 trials), Australia (1 trial), Brazil (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →